Financials data is unavailable for this security.
View more
Year on year Nectar Lifesciences Ltd grew revenues 10.53% from 15.24bn to 16.84bn while net income improved from a loss of 241.83m to a gain of 49.95m.
| Gross margin | 29.64% |
|---|---|
| Net profit margin | 0.37% |
| Operating margin | 5.76% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Nectar Lifesciences Ltd increased its cash reserves by 12.66%, or 22.26m. The company earned 2.25bn from its operations for a Cash Flow Margin of 13.34%. In addition the company used 170.25m on investing activities and also paid 2.05bn in financing cash flows.
| Cash flow per share | 3.00 |
|---|---|
| Price/Cash flow per share | 14.76 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in earnings per share excluding extraordinary items increased 120.65%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
| Div yield(5 year avg) | 0.10% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 0.00% |
| EPS growth(5 years) | -36.29 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 123.60 |
More ▼
